Solara Active Pharma Sciences Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Solara Active Pharma Sciences Ltd trades at ₹514, in a confirmed uptrend and 6 weeks into that stage. That is −5.1% against its own 200-day average. It sits at 31% of a 52-week range of ₹441 to ₹678. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).

Today the stock is in a confirmed uptrend — week 6 of stage 2, confirmed. At ₹514 it trades −5.1% versus its 200-day average and sits at 31% of its 52-week range (₹441–₹678).

Against the market, two honest reads. Cumulative: over the last 8.1 years the stock moved +145% while the NIFTY 500 moved +155% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-07-17) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Solara Active Pharma Sciences Ltd trades at 575.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 24.3×, measured across 6.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 575.0× is about the priciest it has ever traded, against a long-run median of 24.3× measured over 6.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

🚨 Why the multiple sits where it does: over the past year annual EPS moved −1,466.7% against a −15.0% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the −19.5%/yr price move, ~−30.1%/yr came from earnings growth and ~+10.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Solara Active Pharma Sciences Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

4-Factor Sector Score

26.7/100 — rank 21 of 24 in Pharma - API & CRAMS · 77% evidence confidence

Solara Active Pharma Sciences Ltd scores 26.7 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 21. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 8.6 + 3.5 + 8.5 + 6.1 = 26.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Solara Active Pharma Sciences Ltd reported ₹382 Cr of revenue in the Jun 26 quarter, +19.7% year on year. That is the 3rd straight quarter of year-on-year growth. Over 8 years it has compounded at 12.8% a year. The last full year, FY26, came in at ₹1,369 Cr. The last four reported quarters add to ₹1,432 Cr.

FY26 revenue came in at ₹1,369 Cr (+6.6% on the year), capping 8 years at 12.8% compound. The latest quarter (Jun 26) printed ₹382 Cr, +19.7% year on year — the 3rd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +17.1% growth against the decade's 12.8% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +15.6% over the last 4 quarters against +5.0%/yr over the last 8 — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Solara Active Pharma Sciences Ltd's operating margin is 16.0% in the Jun 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged −7.0% to 24.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 16.0%, −2.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged −7.0%–24.0%.

🚨 Why the margin moved: operating margin went −1.6 pp year on year while gross margin went −5.6 pp — the loss came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Solara Active Pharma Sciences Ltd earned ₹16.0 Cr of net profit in the Jun 26 quarter, +45.5% year on year. The full FY26 year was a loss of ₹7.0 Cr. That is 4.2% of the quarter's revenue. The same quarter a year earlier earned ₹11.0 Cr. 7 of the last 12 reported quarters were loss-making.

Jun 26 profit was ₹16.0 Cr, +45.5% year on year. On the full year, FY26 printed ₹−7.0 Cr (−800.0%).

Why profit moved: revenue contributed +19.7% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −164.0% vs revenue +17.1%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 181% of Solara Active Pharma Sciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹153 Cr of operating cash against ₹−7.0 Cr of profit. After ₹70.0 Cr of capital spending, ₹83.0 Cr was left as free cash.

FY26: operating cash of ₹153 Cr against reported profit of ₹−7.0 Cr, leaving free cash of ₹83.0 Cr after ₹70.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 181% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 181%: the cash cycle stretched 38 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Solara Active Pharma Sciences Ltd's cash conversion cycle runs 140 days in FY26, up from 102 days in FY21. Capital spending ran ₹143 Cr over the last 3 years. At FY26 sales of ₹1,369 Cr each day of that cycle holds about ₹3.8 Cr, so roughly ₹525 Cr sits inside the business at any moment.

FY26: debtors at 117 days, inventory at 170 days — roughly 5.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 140 days, looser than FY21's 102.

The full loop: cash goes out to suppliers and production on day 0; stock waits 170 days to sell; customers pay about 117 days after that; and suppliers themselves are paid at 146 days — netting out to the 140-day cycle.

In money terms: at FY26 sales of ₹1,369 Cr, each day of the cycle holds about ₹3.8 Cr — so the 140-day loop keeps roughly ₹525 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹143 Cr over the last 3 fiscal years against ₹302 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹205 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Solara Active Pharma Sciences Ltd earns a ROCE of 5% in FY26. That is up from a trough of −9% in FY24. Return on invested capital clears the cost of that capital by −7.3 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −0.5% net margin on 0.59× asset turns.

FY26 ROCE is 5%, recovered from a FY24 trough of −9% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): −0.5% net margin × 0.59× asset turns × 1.86× balance-sheet leverage ≈ −0.5% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 4.7% − 12.0% = a −7.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Solara Active Pharma Sciences Ltd carries total debt of ₹687 Cr against shareholder equity of ₹1,256 Cr as of Mar 26, a debt-to-equity of 0.55. On the annual view that ratio went from 0.68 in FY22 to 0.55 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹687 Cr against shareholder equity of ₹1,256 Cr — a debt-to-equity of 0.55. On the annual view, debt-to-equity went from 0.68 (FY22) to 0.55 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters added 4.7 points of Solara Active Pharma Sciences Ltd over 8 quarters, the biggest move on the register. That takes promoters to 41.9% of the company. Foreign institutions moved −2.7 points over the same window, to 11.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +4.7 points over 8 quarters to 41.9%; Foreign institutions: −2.7 points over 8 quarters to 11.5%; Domestic institutions: +0.4 points over 8 quarters to 3.7%.

Why the register moved: promoters drove it (+4.7 points), absorbed on the other side by foreign institutions (−2.7 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Solara Active Pharma Sciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions